SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IBRX

ImmunityBio, Inc. (IBRX)

NASDAQ: IBRX · USD
Healthcare · Biotechnology
$6.57-$0.13 (-1.94%)
 
Market cap
$6.99B
Insider Score
Analyst consensus
Market Cap$6.99B+213.1%
Revenue (ttm)$182.57M
Net Income-$1.11B
EPS-$1.06
Shares Out1.06B
PE Ration/a
Forward PE-21.90
Dividendn/a
Ex-Dividend Daten/a
Volume11,095,887
Open$6.72
Previous Close$6.70
Day's Range$6.41 - $6.83
52-Week Range$1.95 - $12.43
Beta0.17
AnalystsStrong Buy
Price Target$14.25(+116.89%)
Earnings DateNov 9, 2026

About IBRX

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Address
3530 John Hopkins Court, San Diego, CA, 92121, United States
Market Cap
6.99 billion
Employees
684
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$7.88M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $12.00 (+82.7%)

2 firms rating IBRX in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+7.03%
5 Days
+0.45%
1 Month
-23.60%
6 Months
-16.77%
1 Year
+213.08%

$IBRX stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of IBRX by members of U.S. Congress

Lisa McClainHouse / RPurchase$1.00K – $15.00KSep 30, 2026
Lisa McClainHouse / RPurchase$1.00K – $15.00KSep 28, 2026

Recently reported changes in IBRX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IBRX's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IBRX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

IBRX Revenue by Segment or Geography

$48.84MTotal
Product revenue, net$48.74M99.79%
Other revenues$104.00K0.21%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New IBRX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IBRX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from IBRX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
45

News check: Mixed coverage: Positive pipeline catalysts (Anktiva FDA filing, trial wins, institutional buying) offset by Q3 earnings miss, Anktiva sales decline, going-concern warning, and sharp stock declines.

Recent Insider Activity

Buys
0
Sells
11
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

RVERTrenchless Fund ETF4.72%
CNCRLoncar Cancer Immunotherapy ETF3.28%
GERMETFMG Treatments, Testing and Advancements ETF3.14%
IDNAiShares Genomics Immunology and Healthcare ETF2.20%
HYPGolden Eagle Dynamic Hypergrowth ETF2.01%
BUZZVanEck Social Sentiment ETF1.98%
BBPVirtus Biotech ETF1.21%
XBIState Street SPDR S&P Biotech ETF0.72%
JSMLJanus Henderson Small Cap Growth Alpha ETF0.50%
CANCTema Oncology ETF0.49%
FNYFirst Trust Mid Cap Growth AlphaDEX Fund0.48%
JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF0.45%

Weight is the stock’s share of each fund’s holdings.